This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
McNeil Consumer & Specialty Pharmaceuticals Inc.
McNeil Consumer & Specialty Pharmaceuticals Inc., a subsidiary of Johnson & Johnson, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1959, the company has established itself as a leader in over-the-counter (OTC) medications, focusing on pain relief, allergy, and gastrointestinal health. With a diverse portfolio that includes well-known brands such as Tylenol, Motrin, and Benadryl, McNeil is recognised for its commitment to quality and consumer trust. The company operates primarily in North America, with significant influence in global markets. Notable achievements include the development of innovative formulations and a strong emphasis on safety and efficacy, positioning McNeil as a trusted name in consumer healthcare. Through its dedication to research and development, McNeil continues to meet the evolving needs of consumers, solidifying its market position in the competitive pharmaceutical landscape.
DitchCarbon Score
How does McNeil Consumer & Specialty Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
McNeil Consumer & Specialty Pharmaceuticals Inc.'s score of 51 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
McNeil Consumer & Specialty Pharmaceuticals Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Kenvue Inc., which may influence its climate commitments and emissions reporting. As of now, McNeil has not publicly outlined any specific reduction targets or initiatives related to carbon emissions. The absence of documented reduction targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. Given its affiliation with Kenvue Inc., any potential climate commitments or emissions data may be cascaded from this parent organisation. Kenvue Inc. is expected to have its own sustainability initiatives and targets, which could indirectly impact McNeil's approach to carbon emissions and climate action. In summary, while McNeil Consumer & Specialty Pharmaceuticals Inc. does not currently report specific emissions data or reduction targets, its relationship with Kenvue Inc. may play a significant role in shaping its future climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 73,841,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 136,832,000 | 000,000,000 | 000,000,000 | - | - |
| Scope 3 | 3,652,178,000 | 0,000,000,000 | 0,000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
McNeil Consumer & Specialty Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
